Vaccines and Therapeutics

Duke DARPA Pandemic Prevention Platform Program (P3)

Duke PI: G. Sempowski (DoD-DARPA HR0011-17-2-0069)

The Duke DARPA Pandemic Prevention Platform (P3) team seeks to apply its experience, innovations, cutting-edge research portfolio, and in-house cGMP manufacturing capabilities (DHVI) to greatly expedite mAb countermeasures for future viral pandemics. The fully integrated platform will be a major advancement in rapid pandemic countermeasure development and will address the significant global challenge pandemic outbreaks have on both civilian and military populations.  (learn more) (DukeHealth Press Release)


Adjuvant Discovery Program

Duke PIs: H. Staats, S. Abraham, G. Sempowski (HHSN272201400054C)

This NIH contract is primarily based in the Duke Department of Pathology but uses the resources of the Duke RBL for Program Management and small animal challenge models for West Nile Virus and influenza virus.  The overall goal of the program is to discover novel vaccine adjuvants to improve vaccine efficacy.  (learn more)


CETR – Center of Excellence in Translational Research (Immunology & Influenza Virology Core)

Duke PI:  G. Sempowski (NIH U19-AI109784)

The purpose of this UNC-based CETR (J. Ting) is to use a novel nanoparticle technology to deliver vaccines and vaccine adjuvants with the goal of improving vaccine outcome.  The overall goal of the Immunology/Influenza Virology Core based on the Duke RBL is to provide comprehensive and centralized biomarker and influenza host response monitoring to enhance product development activities of the center investigators.  Specifically the Duke RBL provides multiplex cytokine/chemokine profiling, high-throughput humoral response monitoring, comprehensive influenza virology support and small animal model support (mice/ferrets). (learn more)


VTEU – Vaccine Treatment and Evaluation Unit (Duke) (Immune Monitoring Core)

Duke PIs: E. Walter, G. Swamy, K. Weinhold, G. Sempowski (HHSN2722013000171)

The National Institute of Allergy and Infectious Disease Vaccine and Treatment Evaluation Units (NIAID VTEUs) play a key role in the development new and improved vaccines and therapies against infectious diseases. VTEUs have run hundreds of clinical trials, many of which have contributed vaccines becoming licensed for use.  The Duke RBL partnered with the DIPC (Department of Surgery) to successfully win a contract to be one of the two national VTEU Immune Monitoring Cores.  The core serves as a central facility to analyze clinical samples for levels of circulating cytokines (Duke RBL) and activation and/or increase(s) in sub-populations of innate immune cells, and T and B cells (DIPC) from multiple DMID-funded VTEU clinical studies. (learn more)